Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Trial Profile

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Lenvatinib (Primary) ; MK 4280 (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms KeyImPaCT; KEYNOTE-495
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Oct 2018 According to an Eisai Inc media release, data from the study will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2018.
    • 09 Oct 2018 Planned End Date changed from 26 May 2022 to 30 May 2022.
    • 09 Oct 2018 Planned primary completion date changed from 26 May 2022 to 30 May 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top